Conductive benzoic acid based polymer containing biomaterial for enhancement of tissue conduction in vitro and in vivo

12264,219

16/634026

July 27, 2018

The present disclosure relates to a biocompatible, electrically conductive biomaterial capable of carrying the electrical potential of a cardiac impulse. The biomaterial comprises a conductive polymer and a biocompatible component. The conductive polymer comprising an aminomethoxybenzoic acid (AMBA) polymer. The present disclosure also relates to treatments, uses and devices using the biocompatible, electrically conductive biomaterial.

UNIVERSITY HEALTH NETWORK (Toronto, CA)

University Health Network (Toronto, CA)

1. A biocompatible conductive biomaterial comprising a conductive polymer and a biocompatible component, the conductive polymer comprising an aminomethoxybenzoic acid (AMBA) polymer, wherein the conductive polymer is covalently conjugated to the biocompatible component, wherein the conductivity of the biomaterial is greater than, at least or equal to about 10 −6 S/cm and wherein the AMBA polymer consists of polymerized AMBA monomers.

2. The biocompatible conductive biomaterial of claim 1 , wherein the AMBA monomer is selected from 3-amino-4-methoxybenzoic acid (3-4-AMBA), 4-amino-2-methoxybenzoic acid (4-2-AMBA), 4-amino-3-methoxybenzoic acid (4-3-AMBA), 2-amino-5-methoxybenzoic acid (2-5-AMBA), and 2-amino-4-methoxybenzoic acid (2-4-AMBA), and mixtures thereof.

3. The biocompatible conductive biomaterial of claim 1 , wherein the biocompatible component is selected from gelatin, chitosan, collagen, fibronectin, elastin, alginate, and derivatives and mixtures thereof or wherein the biocompatible component comprises a synthetic product, optionally a biodegradable synthetic polymer.

4. The biocompatible conductive biomaterial of claim 3 , wherein the biocompatible component is or comprises gelatin.

5. The biocompatible conductive biomaterial of claim 1 , wherein the conductive polymer is covalently conjugated, to the biocompatible component.

6. The biocompatible conductive biomaterial of claim 1 , wherein the biomaterial is a liquid solution, a hydrogel, a membrane, a 3D-patch or sponge, a sheet, or a mesh for grafting.

7. The biocompatible conductive biomaterial of claim 1 , wherein the biomaterial is a hydrogel, optionally wherein the hydrogel is crosslinked.

8. The biocompatible conductive biomaterial of claim 1 , wherein the biocompatible conductive biomaterial has a conductivity of at least or greater than about 10 −5 S/cm, or of at least or greater than about 10 −4 S/cm or least or greater than about 10 −3 S/cm or least or greater than about 10 −2 S/cm.

9. The biocompatible conductive biomaterial of claim 1 , wherein the biocompatible conductive biomaterial has a conductivity of at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than a control biomaterial that does not comprise the conductive polymer.

10. The biocompatible conductive biomaterial of claim 1 , wherein the molar ratio of the conductive polymer and the biocompatible component is about 30:1 to about 60:1.

11. The biocompatible conductive biomaterial of claim 1 further comprising one or more of culture media and cardiomyocytes.

12. A method of ameliorating or treating a heart condition, the method comprising: introducing a biocompatible conductive biomaterial to the heart of a subject in need thereof, wherein the biocompatible conductive biomaterial comprises a conductive polymer and a biocompatible component, the conductive polymer comprising an aminomethoxybenzoic acid (AMBA) polymer, wherein the conductive polymer is covalently conjugated to the biocompatible component, wherein the conductivity of the biomaterial is greater than, at least or equal to about 10 −6 S/cm and wherein the AMBA polymer consists of polymerized AMBA monomers.

13. The method of claim 12 , wherein the heart condition is myocardial infarction, ischemic myocardium, myocardial fibrosis, heart failure, atrioventricular block, arrhythmia, bradycardia or a conduction abnormality.

14. The method of claim 13 , wherein the heart condition is atrioventricular block and the biocompatible conductive biomaterial is for restoring atrioventricular conduction.

15. The method of claim 13 , wherein the heart condition is myocardial fibrosis and the biocompatible conductive biomaterial is introduced into or onto fibrotic scar tissue.

16. The method of claim 15 wherein the biocompatible conductive biomaterial is for reducing the occurrence of cardiac arrhythmia.

17. The method of claim 12 , wherein the biocompatible conductive biomaterial is for reducing the pacing threshold of a cardiac pacemaker or for increasing myocardium reactivity to heart pacing in the subject.

18. The method of claim 14 wherein the heart condition results from cardiac surgery after replacing a cardiac valve.

9289533 March 2016 Schussler et al.
2006/0173058 August 2006 Brown
2015/0366900 December 2015 Li
2016/0032047 February 2016 Murphy
2014121378 August 2014
2015025958 February 2015

Encyclopedia of Polymeric Nanoparticles (Kensuke Naka (2014) pp. 1-6) (Year: 2014). cited by examiner
Cingolani, E. et al. Engineered electrical conduction tract restores conduction in complete heart block: from in vitro to in vivo proof of concept. J Am Coll Cardiol. Dec. 23, 2014;64(24):2575-85. cited by applicant
Etsadashvili, K. et al. Long-term results of high vs. normal impedance ventricular leads on actual (Real-Life) pacemaker generator longevity. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. Feb. 2009;11(2):200-5. cited by applicant
Ra, Li. Gene- and cell-based bio-artificial pacemaker: what basic and translational lessons have we learned? Gene Ther. Jun. 2012;19(6):588-95. cited by applicant
Miake, J. et al. Biological pacemaker created by gene transfer. Nature. Sep. 12, 2002;419(6903):132-3. cited by applicant
Tse, H-F. et al. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation. Sep. 5, 2006;114(10):1000-11. cited by applicant
Xue, T. et al. Mechanistic role of I(f) revealed by induction of ventricular automaticity by somatic gene transfer of gating-engineered pacemaker (HCN) channels. Circulation. Apr. 10, 2007;115(14):1839-50. cited by applicant
Choi, Y-H. et al. Cardiac conduction through engineered tissue. Am J Pathol. Jul. 2006;169(1):72-85. cited by applicant
Mulpuru, S. K. et al. Cardiac Pacemakers: Function, Troubleshooting, and Management: Part 1 of a 2-Part Series. J Am Coll Cardiol. Jan. 17, 2017;69(2):189-210. cited by applicant
Mcvenes, R. et al. The salty dog: serum sodium and potassium effects on modern pacing electrodes. Pacing Clin Electrophysiol PACE. Jan. 2007;30(1):4-11. (Abstract). cited by applicant
Lee, R. J. et al. Development of a model of complete heart block in rats. J Appl Physiol Bethesda Md 1985. Aug. 1998;85(2):758-63. cited by applicant
Dai, W. et al. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol. Aug. 16, 2005;46(4):714-9. cited by applicant
Ifkovits, J. L. et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci U S A. Jun. 22, 2010;107(25):11507-12. cited by applicant
Christman, K. L. et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. Aug. 4, 2004;44(3):654-60. cited by applicant
Maccarter, D. J. et al. Porous electrodes: concept, technology and results. Pacing and clinical electrophysiology : PACE. 1983;6:427-435. cited by applicant
Herrlich, S. et al. Drug release mechanisms of steroid eluting rings in cardiac pacemaker lead electrodes. Conference proceedings : . . . Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2012;2012:681-684. cited by applicant
Elmqvist, H. et al. The carbon tip electrode. Pacing and clinical electrophysiology : PACE. 1983;6:436-439. cited by applicant
Echave, M. C. et al. Gelatin as Biomaterial for Tissue Engineering. Current pharmaceutical design. 2017. (Abstract). cited by applicant
Laughner, J. I. et al. Processing and analysis of cardiac optical mapping data obtained with potentiometric dyes. American journal of physiology. Heart and circulatory physiology. 2012;303:H753-765. cited by applicant
Curtis, M. J. et al. The Lambeth Conventions(II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol. Ther. 139, 213-248 (2013). cited by applicant
Nguyen, T. et al. Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneous hypertensive rat: effects of ramipril and hydralazine. Circulation 98, 2074-2080 (1998). cited by applicant
Ortega, D. F. et al. Non-selective His bundle pacing with a biphasic waveform: enhancing septal resynchronization. Europace. 816-822. (2017). cited by applicant
Mond, H. et al. The high impedance dish electrode—clinical experience with a new tined lead. Pacing and clinical electrophysiology: PACE. 1982;5:529-534. cited by applicant
Masini, M. et al. Activated pyrolytic carbon tip pacing leads: an alternative to steroid-eluting pacing leads? Pacing and clinical electrophysiology: PACE. 1996;19:1832-1835. cited by applicant
Frohlig, G. et al. A fractally coated, 1.3 mm2 high impedance pacing electrode. Pacing and clinical electrophysiology: PACE. 1998;21:1239-1246. cited by applicant
Crossley, G. H. et al. Extraction of chronically implanted coronary sinus leads active fixation vs passive fixation leads. Heart Rhythm. 2016;13:1253-1259. cited by applicant
Mond, H. G. et al. The electrode-tissue interface: the revolutionary role of steroid-elution. Pacing and clinical electrophysiology: PACE. 2014;37:1232-1249. cited by applicant
Netusil, M. Small surface electrodes for cardiac pacing and their effect on the longevity of pacemakers. Cor et vasa. 1972;20:121-128. (Abstract). cited by applicant
Sideris, S. et al. Left Ventricular Pacing through Coronary Sinus Is Feasible and Safe for Patients with Prior Tricuspid Valve Intervention. Pacing and clinical electrophysiology: PACE. 2016;39:378-381. cited by applicant
Furman, S. et al. Pulse duration variation and electrode size as factors in pacemaker longevity. The Journal of thoracic and cardiovascular surgery. 1975;69:382-389. (Abstract). cited by applicant
Kubus, P. et al. Permanent epicardial pacing in children: long-term results and factors modifying outcome. Europace. 2012;14:509-514. cited by applicant
Zhang, H. et al. A flexible and implantable piezoelectric generator harvesting energy from the pulsation of ascending aorta: in vitro and in vivo studies. Nano Energy. 2015;12:296-304. cited by applicant
Stokes, K. B. et al. The mythology of threshold variations as a function of electrode surface area. Pacing and clinical electrophysiology: PACE. 1991;14:1748-1751. cited by applicant
Mawad, D. et al. A conducting polymer with enhanced electronic stability applied in cardiac models. Science Advances 2-11, e1601007, (2016). cited by applicant
Shin, S. R. et al. Carbon-Nanotube-Embedded Hydrogel Sheets for Engineering Cardiac Constructs and Bioactuators. ACS Nano 7, 2369-2380, (2013). cited by applicant
Solazzo, M. et al. The rationale and emergence of electroconductive biomaterial scaffolds in cardiac tissue engineering. APL Bioengineering 3, 041501, (2019). cited by applicant
Tanne, J. et al. Carboxylated or Aminated Polyaniline-Multiwalled Carbon Nanotubes Nanohybrids for Immobilization of Cellobiose Dehydrogenase on Gold Electrodes. Biosensors 4, 370-386, (2014). cited by applicant
Liu, Y. et al. Synthesis and characterization of novel biodegradable and electroactive hydrogel based on aniline oligoner and gelatin. Macromol. Biosci., Oct. 25, 2011 (Oct. 25, 2011), (2012), vol. 12, 241-250. cited by applicant
Huang, L. et al. Synthesis and characterization of electroactive and biodegradable ABA block copolymer of polylactide and aniline pentamer. Biomaterials, Jan. 10, 2007 (Jan. 10, 2007), vol. 28, 1741-1751. cited by applicant

edspgr.12264219